{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-110343","form_type":"8-K","ticker":"GANX","cik":"0001819411","company_name":"Gain Therapeutics, Inc.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.591213+00:00","generated_at":"2026-05-16T21:28:08.326513+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Gain Therapeutics Reports Q3 2025 Results and Phase 1b Data for GT-02287 in Parkinson's Disease","bullets":["Completed enrollment of 21 participants in Phase 1b study of GT-02287, surpassing original target of 15.","Initial data from first nine participants showed improvement in MDS-UPDRS scores, suggesting disease-slowing effect.","Received Australian approval to extend Phase 1b dosing to 12 months; ~80% of participants joined extension.","Net loss for Q3 2025 was $0.15 per share; cash and cash equivalents $8.8 million as of September 30, 2025.","R&D expenses increased to $2.8 million from $2.6 million year-over-year, driven by Phase 1b trial costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-110343","json":"https://secwatch.observer/filing/0001104659-25-110343.json","markdown":"https://secwatch.observer/filing/0001104659-25-110343.md","text":"https://secwatch.observer/filing/0001104659-25-110343.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819411/000110465925110343/0001104659-25-110343-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819411/000110465925110343/ganx-20251112x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-16T21:28:08.326513+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}